Literature DB >> 2040364

Platelet activating factor involvement in splanchnic artery occlusion shock in rats.

F Squadrito1, R Sturniolo, D Altavilla, G Santoro, G M Campo, A Arena, A P Caputi.   

Abstract

Splanchnic artery occlusion shock was induced in anesthetized rats by clamping the splanchnic arteries for 45 min. The survival rate, plasma levels of thromboxane B2 (TxB2) and 6-keto-PGF1 alpha, serum and peritoneal levels of macrophage tumor necrosis factor (TNF alpha), the phagocytotic and killing activity of peritoneal macrophages and white blood cells count were evaluated. Shocked rats died within 2 h, while all sham-shocked rats survived more than 6 h. Plasma TxB2 and 6-keto-PGF1 alpha levels were increased in rats subjected to splanchnic artery occlusion shock compared to the levels in sham-shocked animals. Serum and peritoneal macrophage TNF alpha levels were undetectable in sham-shocked rats, whereas shocked rats exhibited increased levels of TNF alpha. Moreover, splanchnic artery occlusion shock reduced peritoneal macrophage phagocytotic and killing activity, and also produced severe leukopenia. A specific receptor antagonist of platelet activating factor (PAF), L-652, 731 (an i.v. bolus of 3.2 mg/kg 2 min after removal of the clamps followed, 5 min thereafter, by a continuous infusion of 0.16 mg/kg per min for 30 min) significantly increased the survival rate, lowered plasma TxB2 levels and reduced both serum and macrophage TNF alpha levels in shocked rats. In addition, L-652,731 completely restored macrophage phagocytosis, partially improved macrophage killing and significantly inhibited leukopenia. Finally, the administration of L-652,731 had beneficial effects on the cardiovascular changes induced by splanchnic artery occlusion shock. These findings are consistent with the involvement of PAF in splanchnic artery occlusion shock and indicate that PAF produces shock through direct and indirect (TxB2-mediated and TNF alpha-mediated) actions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2040364     DOI: 10.1016/0014-2999(91)90067-z

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Monocytes and lymphocytes as active participants in the pathogenesis of experimental shock.

Authors:  D Altavilla; F Squadrito; L Ammendolia; G Squadrito; G M Campo; P Canale; M Ioculano; C Musolino; A Alonci; A Sardella; G Urna; A Saitta; A P Caputi
Journal:  Inflamm Res       Date:  1996-08       Impact factor: 4.575

2.  Effects of S-ethylisothiourea, a potent inhibitor of nitric oxide synthase, alone or in combination with a nitric oxide donor in splanchnic artery occlusion shock.

Authors:  F Squadrito; D Altavilla; G Squadrito; G M Campo; M Ioculano; P Canale; F Rossi; A Saitta; A P Caputi
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

3.  TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock.

Authors:  P Canale; F Squadrito; D Altavilla; M Ioculano; B Zingarelli; G M Campo; G Urna; A Sardella; G Squadrito; A P Caputi
Journal:  Agents Actions       Date:  1994-10

4.  Contribution of intercellular adhesion molecule 1 (ICAM-1) to the pathogenesis of splanchnic artery occlusion shock in the rat.

Authors:  F Squadrito; D Altavilla; P Canale; M P Ioculano; G M Campo; L Ammendolia; G Squadrito; A Saitta; G Calapai; A P Caputi
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

5.  Improved survival and reversal of endothelial dysfunction by the 21-aminosteroid, U-74389G in splanchnic ischaemia-reperfusion injury in the rat.

Authors:  F Squadrito; D Altavilla; L Ammendolia; G Squadrito; G M Campo; A Sperandeo; P Canale; M Ioculano; A Saitta; A P Caputi
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

6.  Participation of tumour necrosis factor and nitric oxide in the mediation of vascular dysfunction in splanchnic artery occlusion shock.

Authors:  F Squadrito; D Altavilla; P Canale; M Ioculano; G M Campo; L Ammendolia; M Ferlito; B Zingarelli; G Squadrito; A Saitta
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.